Zolpidem extended-release

CNS Drugs

Volumn 20, Issue 5, 2006, Pages 419-426

  Moen, Marit D ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; PLACEBO; ZOLPIDEM; ZOLPIDEM TARTRATE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; LATENT PERIOD; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SLEEP WAKING CYCLE; SOMNOLENCE; TABLET FORMULATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; PRACTICE GUIDELINES; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33646775296     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620050-00006     Document Type: Review

References (15)

1. National Institutes of Health. National Institutes of Health state of the science conference statement: manifestations and management of chronic insomnia in adults June 13-15, 2005. Sleep 2005 Sep 1; 28 (9): 1049-57
2. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65 Suppl. 8: 13-9
3. Sanofi-Synthelabo Inc. Ambien® (zolpidem tartrate tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis. us/ [Accessed 2006 Mar 14]
4. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19 (1): 65-89
5. Sanofi-Synthelabo Inc. Ambien CR™ (zolpidem tartrate extended-release tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us/ [Accessed 2005 Oct 14]
6. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000 Apr; 59 (4): 865-89
7. Stanley N, Hindmarch I, Legangneux E, et al. Zolpidem modified-release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard zolpidem 10 mg [abstract no. 321]. Pharmacotherapy 2005; 25 (10): 1504. Plus oral presentation presented at the 2005 Annual Meeting of the American College of Clinical Pharmacy; 2005 Oct 23-26; San Francisco (CA)
8. Hindmarch I, Stanley N, Legangneux E, et al. Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours postdose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening [abstract no. 0731]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18-23; Denver (CO)
9. Blin O, Micallef-Rolle J, Legangneux E, et al. Zolpidem modified-release 12.5 mg has no residual effects on psychomotor performance and cognitive function in healthy adult subjects [abstract no. 0733]. Sleep 2005; 28 Suppl.: A246. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18-23; Denver (CO)
10. Legangneux E, Hindmarch I, Zobouyan I. Zolpidem modified-release 6.25 mg and double dose 12.5 mg have no residual effects on central nervous system integrative capacity, sensorimotor and psychomotor performance, and immediate and delayed memory recall in healthy elderly subjects [abstract no. 0729]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18-23; Denver (CO)
11. Soubrane C, Walsh J, Roth T. Zolpidem modified-release im-proves sleep induction, sleep maintenance, sleep duration, and quality of sleep without next-day residual effects in adults with primary insomnia [abstract no. 0728]. Sleep 2005; 28 Suppl.: A244-A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18-23; Denver (CO)
12. Roehrs TA, Soubrane C, Roth T. Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia [abstract no. 0725]. Sleep 2005; 28 Suppl.: A244. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18-23; Denver (CO)
13. A receptor channel pharmacology. Curr Pharm Des 2005; 11 (15): 1867-85
14. Data on file. Sanofi-Aventis, 2006
15. Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improved sleep maintenance. Fundam Clin Pharmacol 2006, doi: 10.1111/j.1472-8206.2006.00415.x